Importantly, circRNA-01071|Chr1:223954477-223962708, circRNA-07908|Chr22:38986298-39025349 and circRNA-11015|Chr7:73476868-73478569 regulated the ADAM20, STARD4, and NAV3 mRNAs after GA-Me treatment, which might be one of the reasons why GA-Me activated multiple targets to exert anti-CRC activity. The gene discussed is NAV3; the disease is colorectal carcinoma.